ArticleBreast cancer (Dove Medical Press)2026
Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study.
Shihan Zhou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.